Operating out of the cell, gene and tissue laboratory, our facility is uniquely situated at the Royal Victoria Infirmary, offering access to a large patient population including, paediatric muscular dystrophy, cardiology and haematological cancers.
With our GMP (good manufacturing practice) facilities, clinical research facility and support teams all located on one hospital site we provide a truly integrated and coordinated approach to the delivery of complex trials.
We work in partnership with industry, the NHS and research institutions to deliver innovative advanced therapies at the forefront of modern medicine. We work collaboratively with partners including Newcastle University, Pfizer, Novartis and Autolus to support the delivery of clinical trials.
As an integral member of Newcastle University’s genetic modification safety committee, we are able to offer the highest level of expertise and guidance in relation to the introduction of new gene therapies.
Our highly skilled team routinely handle and process gene therapy, somatic cell therapy and tissue engineered medicinal products as part of an expansive portfolio of clinical trials.
The Newcastle upon Tyne NHS Foundation Trust is one of the UK’s leading providers of licensed CAR-T therapies, working closely with the Northern Centre for Cancer Care and Great North Children’s Hospital.
Providing licensed medicines to both paediatric and adult patients, we are one of only three sites in the UK commissioned to deliver CAR-T to children.
Our team provides the expertise and knowledge required for the safe handling, receipt and distribution of multiple CAR-T medicines, with the capability to expand this provision.
Most recently we have worked with commercial partner Holostem, and colleagues at the Northern Alliance Advanced Therapy Treatment Centre, to establish the supply of licensed medicine Holoclar to a number of approved NHS sites in England.